GSKure

GSKure Overview

GSKure is an IP-based company that owns innovative proprietary GSK-3 peptide inhibitor drug candidates. The company's Kure products are based on a novel design of compounds that target a unique region at the GSK-3 protein surface termed the substrate binding site. The substrate-competitive inhibitors (SCIs) show improved selectivity and low toxicity compared to traditional ATP-competitive inhibitors. GSKures novel SCI strategy for drug design offers significant advantages for clinical practice. Professor Hagit Eldar-Finkelman of Tel Aviv University conducted pioneering studies in developing GSK-3 inhibitors and their therapeutic use in treating human disease.

Latest News

Feb 11, 2016 · www.israel21c.org

growth-positive

Brainnovations graduates first class of neurotech startups

Brainnovations, the country’s first accelerator for brain-related startups, recently graduated its first class of eight companies. The accelerator program comprised three months of lectures, mentoring, and networking. Over 150 investors and mentors recently came out for Brainnovations Demo Day at the Google TLV headquarters to hear from the first class about the technologies they’re developing for Alzheimer’s, depression, spasticity, stroke, brain tumors and other neurodegenerative diseases. The first cycle of Brainnovations exceeded expectations, and the program is now looking forward to the next group of startup teams.

InvestmentExpand

Funding

Team Members

1

Employees: 1-10

Web & Social Links

Locations

Tel Aviv-Yafo, Israel

Photos & Videos

No files yet

GSKure Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info